Key result
Factor Xa inhibitors linked to ~31% lower kidney injury reporting risk vs direct thrombin inhibitors.
Why the study?
Limited real-world studies have explored kidney injury linked to DOACs, particularly differences between direct thrombin inhibitors and factor Xa inhibitors.
Does the use of factor Xa inhibitors compared to direct thrombin inhibitors reduce the reporting risk of kidney injury in patients taking direct oral anticoagulants?
Observational (n=8,116)
Does the use of factor Xa inhibitors compared to direct thrombin inhibitors reduce the reporting risk of kidney injury in patients taking direct oral anticoagulants?
Direct thrombin inhibitors (dabigatran) and the factor Xa inhibitor edoxaban are associated with significantly higher reporting risks of kidney injury compared to other factor Xa inhibitors, highlighting the need for individualized DOAC selection and renal monitoring.
Answers are grounded in this paper and cite their sources.
Factor Xa inhibitors showed lower kidney injury signals than direct thrombin inhibitors; should not change practice pending prospective confirmation.
While direct oral anticoagulants (DOACs) are widely used, limited real-world studies have explored kidney injury linked to DOACs, particularly differences between direct thrombin inhibitors (DTIs) and factor Xa inhibitors (FXaIs). We conducted a comprehensive analysis of kidney injury cases from the FDA Adverse Event Reporting System (FAERS, 2008–2024) and systematically reviewed published case reports, comparing DTIs (dabigatran) with FXaIs (rivaroxaban, apixaban, edoxaban). Among 8,116 reports of suspected DOAC-associated kidney injury, 1,784 were linked to DTIs and 6,332 to FXaIs. Significant reporting rates were observed for DTIs [reporting odds ratio (ROR) = 2.081, 95% CI: 1.979–2.189; proportional reporting ratio (PRR) = 2.044, CI: 1.947–2.147)] and FXaIs (ROR = 1.483, 95% CI: 1.444–1.523; PRR = 1.472, CI: 1.434–1.510). Notably, substantial intra-class variation existed among FXaIs, with edoxaban showing the highest risk signal (ROR = 4.453, 95% CI: 4.021–4.932; PRR = 4.212, 95% CI: 3.831–4.632). Multivariable logistic regression analysis confirmed that significantly lower kidney injury reporting disproportionality signals with FXaIs versus DTIs after adjustment (ROR = 0.687, 95% CI: 0.650–0.727, P < 0.001). Analysis of 32 detailed cases revealed distinct clinical patterns: DTI-associated injury featured higher proteinuria rates (P = 0.029), while FXaI-associated injury occurred more frequently in settings of polypharmacy (P = 0.006) and was associated with poorer renal recovery (P = 0.023). This study demonstrates distinct kidney injury risks among DOAC classes and individual agents, with DTIs and edoxaban showing particularly strong signals. These findings emphasize the need for individualized DOAC selection and enhanced renal monitoring in clinical practice.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) conducted an observational in DOAC-associated kidney injury (n=8,116). Factor Xa inhibitors vs. Direct thrombin inhibitors (dabigatran) was evaluated on Kidney injury reporting disproportionality (ROR 0.687, 95% CI 0.650-0.727, p=<0.001). Factor Xa inhibitors were associated with a lower reporting risk of kidney injury compared to direct thrombin inhibitors.
Synapse has enriched 10 related papers. Consider them for comparative context: